NANOBIOTIX partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers
NANOBIOTIX PARTNERS WITH THE PROVIDENCE CANCER INSTITUTE TO RUN IMMUNOTHERAPEUTIC PRECLINICAL RESEARCH IN PANCREATIC CANCERS Paris, France and Cambridge, Massachusetts, USA, January 11, 2018 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late …